Small LDL particle number

2 papers1 finding

Human trial2

Interventions

1

Obicetrapib

downin humans1

1 study

Obicetrapib decreases small LDL particle number in humans (-100.61% (95% CI: -110.65 to -90.57)).
“yielding a between-group difference of -100.61% (95% CI: -110.65 to -90.57, P<0.0001)”
Human trialin patients with ASCVD and/or familial hypercholesterolemia receiving maximally tolerated lipid-lowering therapyoral10 mg daily
Cholesteryl Ester Transfer Protein (CETP) Inhibition with Obicetrapib Produces Substantial Reductions in LDL Particles: Pooled Analysis of BROOKLYN and BROADWAY Phase 3 Clinical Trials
AHA Scientific Sessions 2025 abstract3 Nov 2025

More on Obicetrapib

Latest

1 in 12 months

AHA Scientific Sessions 2025 Abstract3 Nov

Cholesteryl Ester Transfer Protein (CETP) Inhibition with Obicetrapib Produces Substantial Reductions in LDL Particles: Pooled Analysis of BROOKLYN and BROADWAY Phase 3 Clinical Trials

Randomised trial in peopleInterventions

ENDO 2025 Abstract23 Oct

SAT-133 Addition of Metformin Does Not Alter Metabolic Impact of Combined Oral Contraceptive Pills in Hyperandrogenic Women with Polycystic Ovary Syndrome: Findings from COMET-PCOS Trial

Randomised trial in 240 peopleMetformin